Check-Cap Ltd. (CHEK): Price and Financial Metrics


Check-Cap Ltd. (CHEK): $0.99

-0.02 (-1.98%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

CHEK Stock Price Chart Interactive Chart >

Price chart for CHEK

CHEK Price/Volume Stats

Current price $0.99 52-week high $4.49
Prev. close $1.01 52-week low $0.24
Day low $0.98 Volume 522,800
Day high $1.02 Avg. volume 10,579,832
50-day MA $1.07 Dividend yield N/A
200-day MA $1.35 Market Cap 45.78M

Check-Cap Ltd. (CHEK) Company Bio


Check-Cap Ltd. is a clinical stage medical diagnostics company engaging in the development of ingestible imaging capsule system for colorectal cancer screening. The company was founded by Yoav Kimchy in April 2005 and is headquartered in Isfiya, Israel.


CHEK Latest News Stream


Event/Time News Detail
Loading, please wait...

CHEK Latest Social Stream


Loading social stream, please wait...

View Full CHEK Social Stream

Latest CHEK News From Around the Web

Below are the latest news stories about Check-Cap Ltd that investors may wish to consider to help them evaluate CHEK as an investment opportunity.

Check-Cap Appoints Dr. Hanit Brenner-Lavie as Vice President of Clinical Affairs

Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test to detect polyps before they may transform into colorectal cancer (CRC), today announced the appointment of Dr. Hanit Brenner-Lavie as Vice President of Clinical Affairs. Dr. Brenner-Lavie will be responsible for leading the Company's overall clinical strategy and impl

Yahoo | September 1, 2021

Check-Cap Reports Second Quarter 2021 Financial Results and Corporate Update

Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test to detect polyps before they may transform into colorectal cancer (CRC), today announced financial results and provided a corporate update for the second quarter and six months ended June 30, 2021.

Yahoo | August 5, 2021

We Think Check-Cap (NASDAQ:CHEK) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | July 1, 2021

Check-Cap Shares Are Trading Lower On Capital Raise Of $35M To Support C-Scan Development

Check-Cap Ltd (NASDAQ: CHEK) has announced a registered direct offering of 25.9 million shares, with approximately $35 million in gross proceeds. Each ordinary share is being sold together with one short-term warrant at a combined price of $1.35 per common share and accompanying warrant. The short-term warrants will have a term of two and one-half years following the date of issuance, with an exercise price of $1.50 per ordinary share. Full exercise of the warrants would generate additional gros

Yahoo | June 30, 2021

Check-Cap Ltd. Announces $35 Million Registered Direct Offering

Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test, to detect polyps before they may transform into colorectal cancer (CRC), today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 25,925,926 of the Company's ordinary shares and acc

Yahoo | June 30, 2021

Read More 'CHEK' Stories Here

CHEK Price Returns

1-mo 2.91%
3-mo -38.51%
6-mo -46.49%
1-year 168.44%
3-year -72.88%
5-year -95.77%
YTD 115.22%
2020 -73.26%
2019 -20.00%
2018 -79.41%
2017 -62.98%
2016 24.34%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7812 seconds.